Spots Global Cancer Trial Database for mpn
Every month we try and update this database with for mpn cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance | NCT04285086 | Essential Throm... | Ropeginterferon... Anagrelide | 18 Years - | PharmaEssentia | |
| Haplo Peripheral Blood Sct In GVHD Prevention | NCT04473911 | GVHD AML ALL MDS MPN CMML Hodgkin Lymphom... Non Hodgkin Lym... Blood Stem Cell... Graft Vs Host D... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myelomo... Chemosensitive ... | FLUDARABINE CYCLOPHOSPHAMID... TBI Melphalan Sirolimus Mycophenolate m... RGI-2001 CYCLOPHOSPHAMID... | 18 Years - 80 Years | Massachusetts General Hospital | |
| Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation | NCT02492737 | Acute Myeloid L... Myelodysplastic... Hematologic Mal... | AG881 | 18 Years - | Agios Pharmaceuticals, Inc. | |
| Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance | NCT04285086 | Essential Throm... | Ropeginterferon... Anagrelide | 18 Years - | PharmaEssentia | |
| Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies | NCT01606579 | Acute Myeloid L... Chronic Myeloid... | PRI-724 PRI-724 PRI-724 | 18 Years - | Prism Pharma Co., Ltd. | |
| Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) | NCT02410551 | Myeloproliferat... | Pacritinib Busulfan Questionnaires Phone Calls Allogeneic Stem... Fludarabine | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Haplo Peripheral Blood Sct In GVHD Prevention | NCT04473911 | GVHD AML ALL MDS MPN CMML Hodgkin Lymphom... Non Hodgkin Lym... Blood Stem Cell... Graft Vs Host D... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myelomo... Chemosensitive ... | FLUDARABINE CYCLOPHOSPHAMID... TBI Melphalan Sirolimus Mycophenolate m... RGI-2001 CYCLOPHOSPHAMID... | 18 Years - 80 Years | Massachusetts General Hospital | |
| Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. | NCT04866056 | Myelodysplastic... Myeloproliferat... Myelofibrosis | Jaktinib azacitidine | 18 Years - | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms | NCT05732961 | Myelodysplastic... Myeloproliferat... Anemia | Luspatercept | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET | NCT05482971 | Essential Throm... | Ropeginterferon... | 18 Years - | PharmaEssentia | |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | NCT03952039 | Primary Myelofi... Post-Polycythem... Myelofibrosis | FEDRATINIB Best Available ... | 18 Years - | Celgene | |
| Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation | NCT02492737 | Acute Myeloid L... Myelodysplastic... Hematologic Mal... | AG881 | 18 Years - | Agios Pharmaceuticals, Inc. | |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera | NCT03287245 | Polycythemia Ve... | Idasanutlin | 18 Years - | Hoffmann-La Roche | |
| Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms | NCT05732961 | Myelodysplastic... Myeloproliferat... Anemia | Luspatercept | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | NCT04996875 | Advanced System... SM With an Asso... Mast Cell Leuke... Aggressive Syst... | bezuclastinib | 18 Years - | Cogent Biosciences, Inc. | |
| To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) | NCT04551053 | Myelofibrosis Primary Myelofi... Post Essential ... Post Polycythem... | parsaclisib ruxolitinib placebo | 18 Years - | Incyte Corporation | |
| Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | NCT02393248 | Lung Cancer Solid Tumor Gastric Cancer Urothelial Canc... Endometrial Can... Multiple Myelom... Myeloproliferat... Breast Cancer Cholangiocarcin... UC MPN | Pemigatinib Gemcitabine Pembrolizumab Docetaxel Trastuzumab Retifanlimab Cisplatin | 18 Years - | Incyte Corporation | |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | NCT03952039 | Primary Myelofi... Post-Polycythem... Myelofibrosis | FEDRATINIB Best Available ... | 18 Years - | Celgene | |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | NCT03952039 | Primary Myelofi... Post-Polycythem... Myelofibrosis | FEDRATINIB Best Available ... | 18 Years - | Celgene | |
| An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms | NCT05123365 | Myeloproliferat... MPN Essential Throm... Polycythemia Ve... Myelofibrosis | N-Acetylcystein... | 18 Years - | University of California, Irvine | |
| Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm | NCT05025488 | Myelofibrosis Essential Throm... MPN | Peptide-based v... Poly ICLC | 18 Years - | Icahn School of Medicine at Mount Sinai |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
